View Older Stories View More Recent Stories

May 7, 2025 06:00AM PTC Therapeutics (PTCT) PT Lowered to $42 at Barclays
May 7, 2025 05:17AM PTC Therapeutics (PTCT) PT Lowered to $67 at JPMorgan
May 7, 2025 03:35AM Citi Upgrades PTC Therapeutics (PTCT) to Neutral
May 6, 2025 04:04PM PTC Therapeutics (PTCT) reported revenue at $190 million, provides guidance
May 5, 2025 02:48PM Leerink Partners Reiterates Market Perform Rating on PTC Therapeutics (PTCT)
May 5, 2025 07:01AM PTC Therapeutics (PTCT): PTC518 PIVOT-HD Study Achieves Primary Endpoint
Apr 25, 2025 09:00AM PTC Therapeutics (PTCT) Receives Positive CHMP Opinion for Sephience™ (sepiapterin) for the Treatment of Children and Adults Living with Phenylketonuria
Apr 12, 2025 04:00AM Biotech sector Q1 earnings preview from RBC Capital Markets
Apr 2, 2025 07:04AM Smid cap biotech investors must stop chasing binary events says Cantor Fitzgerald
Apr 1, 2025 06:17AM Wells Fargo Releases Regular Quarterly Update to Tactical Ideas List
Mar 28, 2025 09:00AM PTC Therapeutics (PTCT) Provides Regulatory Update on Translarna in Europe
Mar 20, 2025 08:03AM PTC Therapeutics (PTCT) Presents New Sepiapterin Data from Ongoing Studies
Mar 11, 2025 05:20AM BofA Securities Upgrades PTC Therapeutics (PTCT) to Neutral
Mar 7, 2025 07:12AM Scotiabank Starts PTC Therapeutics (PTCT) at Sector Perform
Mar 3, 2025 08:46AM Cantor Fitzgerald Reiterates Overweight Rating on PTC Therapeutics (PTCT)
Feb 27, 2025 04:12PM PTC Therapeutics (PTCT) Misses Q4 EPS by 6c
Feb 19, 2025 10:31AM PTC Therapeutics (PTCT) PT Raised to $60 at TD Cowen Following FDA Acceptance and Priority Review for Vatiquinone NDA
Feb 19, 2025 07:01AM PTC Therapeutics (PTCT) Announces FDA Acceptance and Priority Review for Vatiquinone NDA for the Treatment of Children and Adults with Friedreich's Ataxia
Feb 3, 2025 06:47AM PTC Therapeutics (PTCT) PT Raised to $113 at Cantor Fitzgerald
Jan 29, 2025 07:09AM PTC Therapeutics (PTCT) PT Raised to $50 at TD Cowen
Jan 13, 2025 12:50PM RBC Capital Explores Biotech Implications Following Cavazzoni's Departure from the FDA
Jan 13, 2025 09:08AM PTC Therapeutics (PTCT) Provides Update on Commercial Performance and R&D Pipeline at 43rd Annual J.P. Morgan Healthcare Conference
Jan 6, 2025 10:35AM TD Cowen: '10 Potential "Thome Run" Catalysts to Watch in 2025'
Dec 19, 2024 08:02AM PTC Therapeutics (PTCT) Announces Vatiquinone NDA Submission to FDA for the Treatment of Children and Adults Living with Friedreich Ataxia
Dec 12, 2024 08:54PM Morgan Stanley Upgrades PTC Therapeutics (PTCT) to Overweight
Dec 12, 2024 03:01PM PTC Therapeutics (PTCT) spreader of 2186 contracts of January 35 and January 45 puts
Dec 4, 2024 05:50AM PTC Therapeutics (PTCT) PT Raised to $32 at Citi
Dec 3, 2024 07:04AM PTC Therapeutics (PTCT) PT Raised to $42 at Goldman Sachs
Dec 3, 2024 06:25AM PTC Therapeutics (PTCT) PT Raised to $70 at Baird
Dec 2, 2024 04:14PM JPMorgan Reiterates Overweight Rating on PTC Therapeutics (PTCT)
Dec 2, 2024 04:12PM RBC Capital Upgrades PTC Therapeutics (PTCT) to Outperform, 'NVS HD Deal Meaningfully Improves Fundamentals'
Dec 2, 2024 07:02AM PTC Therapeutics (PTCT) Enters into a Global License and Collaboration Agreement with Novartis (NVS) for PTC518 Huntington's Disease Program
Nov 30, 2024 10:00PM JPMorgan is out with its 2025 outlook for biotech stocks
Nov 27, 2024 07:16AM PTC Therapeutics (PTCT) PT Raised to $52 at Baird
Nov 27, 2024 07:00AM PTC Therapeutics (PTCT) to Sell Priority Review Voucher for $150M
Nov 27, 2024 05:06AM PTC Therapeutics (PTCT) all put ratio 11.7 calls to 1 put into quarter results
Nov 26, 2024 04:44PM After-hours movers: HP Inc., Dell Technologies, Workday and more
Nov 26, 2024 04:31PM PTC Therapeutics (PTCT) Announces Topline Results of CardinALS Trial of Utreloxastat in ALS Patients
Nov 7, 2024 04:08PM PTC Therapeutics (PTCT) Tops Q3 EPS by 12c, provides guidance
Oct 30, 2024 07:00AM PTC Therapeutics (PTCT) Announces FDA Acceptance of Translarna NDA Resubmission
Oct 18, 2024 06:31AM PTC Therapeutics (PTCT) Reports CHMP Maintained Negative Opinion on Translarna Reexamination
Oct 15, 2024 05:42AM Citi Reiterates Sell Rating on PTC Therapeutics (PTCT)
Oct 14, 2024 04:30PM PTC Therapeutics (PTCT) Announces FDA Target Regulatory Action Date of July 29, 2025 for Sepiapterin and Lancet Publication of Phase 3 Trial Results
Oct 10, 2024 08:22AM Raymond James Resumes PTC Therapeutics (PTCT) at Market Perform
Oct 9, 2024 06:43AM Baird Reiterates Outperform Rating on PTC Therapeutics (PTCT)
Oct 9, 2024 05:34AM Goldman Sachs Reiterates Sell Rating on PTC Therapeutics (PTCT)
Oct 8, 2024 11:28AM TD Cowen Reiterates Hold Rating on PTC Therapeutics (PTCT)
Oct 8, 2024 08:04AM PTC Therapeutics (PTCT) Announces Positive Results from Long-Term Treatment Studies and Updates on Regulatory Progress for Vatiquinone Friedreich Ataxia Program
Oct 1, 2024 09:05AM PTC Therapeutics (PTCT) Announces FDA Acceptance for Filing of NDA for Sepiapterin
Sep 27, 2024 06:58AM Baird Reiterates Outperform Rating on PTC Therapeutics (PTCT)
View More Recent Stories View Older Stories